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Propositions 
 
1. Analysis of Functional Annotation can be used to create a rationale for novel 
combination therapies, and therefore may prevent unnecessary trial-and-error 
combination studies (this thesis). 
 
2. Preclinical research suggests that prostate cancer patients may benefit from 
treatment with antimitotic agents such as aurora kinase inhibitors and polo-like 
kinase 1 inhibitors, particularly in combination with other therapies (this thesis). 
 
3. Retrospective clinical studies suggest that patients with metastatic castrate-
resistant prostate cancer who responded well to docetaxel treatment may need to 
be treated with cabazitaxel before abiraterone as second-line therapy when the 
patient’s condition allows for additional chemotherapy (this thesis). 
 
4. Eg5 is a marker for docetaxel response and tumor aggressiveness in prostate 
cancer patients (this thesis). 
 
5. Preclinical research indicates that irinotecan and cetrimonium bromide may 
prevent or reduce prostate cancer metastases by selectively targeting prostate 
cancer cells deficient in the metastasis suppressor gene N-myc downregulated 
gene 1 (this thesis). 
 
6. A current priority in prostate cancer research is to identify markers predicting 
disease and therapy outcome. 
 
7. The United States Food and Drug Administration and similar institutions need to 
involve cost of a cancer therapy in their decision to approve new drugs. 
 
8. Despite the introduction of various targeted therapies, chemotherapy remains of 
importance for the treatment of patients with metastatic castrate-resistant prostate 
cancer. 
 
9. The approval of radium-223 for the treatment of bone metastases proves that 
targeting of metastases is an effective antitumor strategy in prostate cancer. 
 
10. The roots of education are bitter, but the fruit is sweet – Aristoteles (384-322 BC) 
 
11. The good physician treats the disease; the great physician treats the patient who 
has the disease – William Osler (1849-1919) 
 
12. Medicine sometimes snatches away health, sometimes gives it – Ovidius (43BC-
17AD) 
